Pharmaceuticals, Biotechnology and Life Sciences
Lupin got the EC approval of NaMuscla for reducing myotonia symptoms in adult patients, and has partnering discussions ongoing for commercialization of NaMuscla in European territories outside Germany and the UK.
Royal College of Surgeons in Ireland team of researchers (RCSI) said Tuesday they have developed a new treatment for tuberculosis (TB), a potential practical treatment to be scaled-up and mass-produced for clinical testing.
Novartis has secured its crizanlizumab (SEG101) Breakthrough Therapy designation US Food and Drug Administration (FDA), for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease (SCD).
Denali Therapeutics and Sanofi in partnership have started dosing patients in a clinical Phase 1b study of DNL747 in patients with ALS.
Swiss-based global biopharmaceutical company Debiopharm Group will break up partnership with Allergan, and will transfer commercialisation licence for Trelstar in the US and Canada.
OncoSec Medical Incorporated and GOG Foundation will jointly work to conduct a registration-enabled study of Tavo (tavokinogene telseplasmid) in women with recurrent/persistent cervical cancer (OMS-150), it was announced on Monday.
Mirati Therapeutics and Bristol-Myers Squibb will work together on evaluating the combination of sitravatinib and nivolumab (OPDIVO), in Mirati’s planned Phase 3 trial in second line non-small cell lung cancer (NSCLC) patients who have progressed following treatment with a platinum-based regimen and a checkpoint inhibitor.
Stemedica Cell Technologies today announced positive results from its Phase I/IIa clinical study for the treatment of ischemic stroke.
Allergan announced positive 3-month topline results from the second pivotal clinical trial of Bimatoprost SR, a first-in-class sustained-release, biodegradable implant for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, while the global pharmaceutical leader noted the positive results from the first Phase 3 trial were reported in June 2018.
A Dutch maker of of transformative RNA medicines for the treatment of severe genetic rare diseases, ProQR Therapeutics, has got the U.S. Food and Drug Administration (FDA) tips for a Phase 2/3 pivotal trial Illuminate for sepofarsen, in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene, the leading genetic cause of childhood blindness.